GlassScriptPhysician profile
Hashim S Raza
NPI 1891840237
$14,034.46
in general payments reported to CMS, 2019-2025
62 companies · $1,564 in 2025
The $1,564 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,839 · 2020: $1,192 · 2021: $2,662 · 2022: $2,747 · 2023: $2,029 · 2024: $2,002 · 2025: $1,564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,594 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,594.35 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,547.20 | 2020-2025 | |
| Novo Nordisk INC | $1,729.83 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,301.14 | 2019-2025 | |
| Lilly USA, LLC | $1,269.52 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $934.58 | 2019-2025 | Repatha, Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $853.71 | 2019-2025 | Farxiga, Saphnelo, Enhertu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $463.82 | 2019-2024 | Cyltezo, Jardiance |
| Janssen Pharmaceuticals, INC | $415.34 | 2019-2024 | Spravato, Xarelto |
| Novartis Pharmaceuticals Corporation | $323.19 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $296.99 | 2020-2025 | Verquvo, Belsomra, Steglatro |
| Glaxosmithkline, LLC. | $295.77 | 2020-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Biohaven Pharmaceuticals, INC. | $283.60 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $274.60 | 2020-2023 | Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $271.09 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $252.96 | 2019-2025 |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hashim Raza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.